Literature DB >> 1154276

Revascularization of the profunda femoris artery in aortoiliac occlusive disease.

P Welsh, R Repetto.   

Abstract

We have presented both early and late results in 236 extremities revascularized by aortofemoral, axillofemoral, or femorofemoral bypass grafts for severe atherosclerotic disease. The superficial femoral artery was occluded in all patients and initial outflow was provided solely through the profunda femoris system. Five different categories have been defined based on the procedure utilized to insure patency of the proximal profunda system. Subsequent patency rates are determined for each category. In reviewing our total experience the profunda femoris system was adequate to maintain both graft patency and limb viability in 90.3 percent of extremities in the early postoperative period. This declined to 78.5 percent at 5 year follow-up. Femoropopliteal bypass was required in 16 patients within the first postoperative month to maintain graft patency or relieve persistent ischemia. It is suggested that the addition of femoropopliteal bypass may improve inmediate and long-term patency rates and offer greater assurance that ischemia will be relieved.

Entities:  

Mesh:

Year:  1975        PMID: 1154276

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  A technique for profunda femoris artery reconstruction. Hemodynamic assessment and functional results.

Authors:  R J Feldhaus; A V Sterpetti; R D Schultz; D J Peetz
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

2.  [Transplant occlusion following aortofemoral bifurcation bypass: causes, therapeutic measures and results].

Authors:  W Hepp; K de Jonge; M Langer
Journal:  Langenbecks Arch Chir       Date:  1984

3.  HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis.

Authors:  Mi Kwon Son; Ye-Lim Ryu; Kyung Hee Jung; Hyunseung Lee; Hee Seung Lee; Hong Hua Yan; Heon Joo Park; Ji-Kan Ryu; Jun-Kyu Suh; Sungwoo Hong; Soon-Sun Hong
Journal:  Sci Rep       Date:  2013-12-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.